Details of the Drug Combination

General Information of Drug Combination (ID: DCHUHWE)

Drug Combination Name
Succinylcholine Rocuronium
Indication
Disease Entry Status REF
Neuromuscular Blockade Phase 1 [1]
Component Drugs Succinylcholine   DM2ET1M Rocuronium   DMY9BMK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Succinylcholine
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [2]
Spasm MB47.3 Approved [3]
Succinylcholine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Succinylcholine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Increases Response To Substance [6]
Myoglobin (MB) OTYWYL2D MYG_HUMAN Increases Secretion [7]
------------------------------------------------------------------------------------
Indication(s) of Rocuronium
Disease Entry ICD 11 Status REF
Muscle spasm MB47.3 Approved [4]
Rocuronium Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Neuronal acetylcholine receptor alpha-2 (CHRNA2) TTF4E0J ACHA2_HUMAN Antagonist [8]
------------------------------------------------------------------------------------
Rocuronium Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [9]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01441960) Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
2 Succinylcholine FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4004).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906.
6 Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
7 Midazolam pretreatment does not ameliorate myoglobinemia or the clinical side effects of succinylcholine. J Clin Anesth. 1993 Sep-Oct;5(5):414-8. doi: 10.1016/0952-8180(93)90107-p.
8 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
9 Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
10 Drug Interactions in Infectious Diseases.